Clik here to view.
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK...
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad...
View ArticleClik here to view.
CureVac Reports Progress in Intellectual Property Infringement Case Against...
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validity...
View ArticleClik here to view.
CureVac to Report Third Quarter and First Nine Months 2023 Financial Results...
TÜBINGEN, Germany / BOSTON, USA – October 31, 2023CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid...
View ArticleClik here to view.
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu...
COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of...
View ArticleClik here to view.
CureVac Announces Financial Results for the Third Quarter and First Nine...
Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with...
View ArticleClik here to view.
CureVac Announces Decision of German Federal Patent Court in Broad Patent...
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other...
View ArticleClik here to view.
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine...
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile Monovalent mRNA vaccine candidate,...
View ArticleClik here to view.
[Form 6-K only / English only] CureVac CEO Alexander Zehnder Acquires Common...
TÜBINGEN, Germany / BOSTON, USA – January 17, 2024CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
View ArticleClik here to view.
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza...
Seasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults Potentially differentiated, multivalent...
View ArticleClik here to view.
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer...
Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise Collaboration aims to develop novel,...
View ArticleClik here to view.
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and...
TÜBINGEN, Germany / HOUSTON, Texas, USA – April 18, 2024CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
View ArticleClik here to view.
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and...
View ArticleClik here to view.
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will...
View ArticleClik here to view.
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023...
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA)...
View ArticleClik here to view.
CureVac Announces Financial Results for the First Quarter of 2024 and...
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1)...
View ArticleClik here to view.
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from...
View ArticleClik here to view.
[English only] CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany/BOSTON, USA – June 24, 2024CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger...
View ArticleClik here to view.
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to...
View ArticleClik here to view.
CureVac Initiates Strategic Restructuring to Align Resources with Focus on...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of...
View ArticleClik here to view.
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)...
View Article